Abstract
Venom immunotherapy (VIT) is highly effective in patients with Hymenoptera venom allergy (HVA), with a capacity to protect against reactions to stings that lasts even after its cessation after a recommended duration of at least 5 years.1 However, in patients with severe initial systemic reactions and elevated baseline serum tryptase (which is currently estimated as >11.4 mcg/L) or mast cell disorders, VIT may be less protective, requiring an increase in maintenance common dosage of 100 mcg up to 200 mcg.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
